Earnings From American & Southwest, Q2 GDP Data: What to Watch
Unusual Options Activity: ACI, AZN and Others Attract Market Bets, ACI V/OI Ratio Reaches 208.3
AstraZeneca Q2 2024 Earnings Preview
Notable Earnings Before Thursday's Open
AstraZeneca Grows Oncology Portfolio With Pinetree's EGFR Degrader
UBS Sticks to Its Sell Rating for AstraZeneca (AZN)
Merck Competes With Sanofi/AstraZeneca As Its RSV Treatment Drug Meets Primary Goal In Late-Stage Study In Infants
AstraZeneca Secures Global License for Pinetree's Novel Cancer Candidate
Unusual Options Activity: X, FTAI and Others Attract Market Bets, X V/OI Ratio Reaches 130.4
Pinetree Therapeutics Announces Exclusive Option and Global License Agreement for Preclinical EGFR Degrader Candidate With AstraZeneca
Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?
AstraZeneca Expected to Post Higher Revenue, Lower Core Earnings -- Earnings Preview
AstraZeneca Says Voydeya Approved In Canada As Add-on To Ravulizumab Or Eculizumab For PNH
Merck RSV Therapy Succeeds in Infants in Challenge to Sanofi, Astra
Voydeya Approved in Canada as Add-on Therapy to Ravulizumab or Eculizumab for Adults With the Rare Disease PNH Who Have Residual Hemolytic Anemia Due to Extravascular Hemolysis
AstraZeneca: Strong Growth and Resilience Justify Buy Rating
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
Is AstraZeneca (AZN) a Portfolio Must-Have Pre-Q2 Earnings?
The Race to Develop the 'Holy Grail' of Weight-loss Drugs
Here Are Big Pharma's Leading Blockbuster Makers